About Zimmer Biomet Holdings
Zimmer Biomet Holdings, Inc., formerly Zimmer Holdings, Inc., is engaged designing, manufacturing and marketing orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The Company's products and solutions helps treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. The Company manages its operations through three geographic operating segments: the Americas, consists of the United States and includes other North, Central and South American markets; EMEA, consists of Europe and includes the Middle East and African markets, and Asia Pacific, consists of Japan and includes other Asian and Pacific markets. Its four product category segments include Americas Spine, Bone Healing Craniomaxillofacial and Thoracic, and Dental.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Appliances & Equipment
- Sub-Industry: N/A
- Exchange: NYSE
- Symbol: ZBH
- Previous Close: $116.38
- 50 Day Moving Average: $115.72
- 200 Day Moving Average: $116.44
- 52-Week Range: $200,399,000.00 - $95.44
- Trailing P/E Ratio: 77.95
- Foreward P/E Ratio: 12.46
- P/E Growth: 1.40
- Market Cap: $23.43B
- Outstanding Shares: 200,399,000
- Beta: 1.2
- Net Margins: 3.90%
- Return on Equity: 16.66%
- Return on Assets: 6.07%
Companies Related to Zimmer Biomet Holdings:
- Debt-to-Equity Ratio: 1.11%
- Current Ratio: 1.95%
- Quick Ratio: 1.13%
What is Zimmer Biomet Holdings' stock symbol?
Zimmer Biomet Holdings trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZBH."
How often does Zimmer Biomet Holdings pay dividends? What is the dividend yield for Zimmer Biomet Holdings?
Zimmer Biomet Holdings declared a quarterly dividend on Monday, December 19th. Stockholders of record on Friday, December 30th will be given a dividend of $0.24 per share on Friday, January 27th. This represents a $0.96 annualized dividend and a dividend yield of 0.82%. The ex-dividend date is Wednesday, December 28th.
Where is Zimmer Biomet Holdings' stock going? Where will Zimmer Biomet Holdings' stock price be in 2017?
22 brokers have issued 12 month target prices for Zimmer Biomet Holdings' stock. Their forecasts range from $95.00 to $155.00. On average, they expect Zimmer Biomet Holdings' stock price to reach $133.68 in the next year.
When will Zimmer Biomet Holdings announce their earnings?
Zimmer Biomet Holdings is scheduled to release their next quarterly earnings announcement on Wednesday, April, 26th 2017.
What are analysts saying about Zimmer Biomet Holdings stock?
Here are some recent quotes from research analysts about Zimmer Biomet Holdings stock:
- Needham & Company LLC analysts commented, "We hosted a dinner and investor meetings with Dan Florin, Senior Vice President and CFO, and Bob Marshall, Treasurer and Vice President of Investor Relations this week in New York City. We think that the discussion was upbeat and highlighted ZBH's progress in addressing its manufacturing challenges, its non-recon business performance, margin opportunities, and cash flow outlook. The meetings reinforced our view that ZBH should be able to drive its revenue growth to sustainable mid-single digit growth with a combination of market growth in recon and above-market growth in its non-recon businesses. We reiterate our Strong Buy rating." (2/17/2017)
According to Zacks Investment Research, "Over the past six months, Zimmer Biomet traded neck on neck with the Zacks categorized Medical Product industry. However, situation deteriorated in late October with the company posting a disappointing third quarter 2016. Sluggish top-line show outside the U.S. significantly hampered the company’s overall performance. Poor sales in Knee also concern us. With the company lowering its full-year 2016 guidance, we expect this gloomy scenario to continue. On a positive note, we still look forward to the expected synergy from the recently completed LDR Holding acquisition, which should broaden and complement the company's musculoskeletal offering. This transaction is also expected to drive significant financial benefits for the consolidated company post 2017." (12/16/2016)
J P Morgan Chase & Co analysts commented, "Zimmer’s re-acceleration continued into 2Q earnings as sales grew 4.5% pro- forma and 2.6% organic excluding an extra selling day. Organic growth came in well above the Street’s call for 1.6% organic growth and buy-side calls for 1.9% (see our recent survey here). The sales beat was broad based with each business performing in-line or better than Street estimates with Knees (+$2M), Hips (+$9M), SET (+$20M), and Dental (+$5M) as the standout performers in the quarter. While gross margins were lower than expected (70bps), this was tempered by in-line operating expense and a better than expected tax rate including benefits from the early adoption of ASU 2016-09 (+$0.01). When factoring in the better than expected top-line, this drove a $0.05 Cash EPS beat. With Zimmer’s turnaround tracking ahead of expectations, we reiterate our Overweight rating on the stock and raise our price target from $134 to $148 (Y/E 17), conservatively valuing the stock at 15x 2018 Cash EPS, a 20% discount to its peers." (7/29/2016)
Who owns Zimmer Biomet Holdings stock?
Zimmer Biomet Holdings' stock is owned by many different of retail and institutional investors. Top institutional shareholders include State Street Corp (3.99%), FMR LLC (3.32%), Investec Asset Management LTD (1.06%), Hotchkis & Wiley Capital Management LLC (0.79%), Janus Capital Management LLC (0.59%) and Russell Investments Group Ltd. (0.49%). Company insiders that own Zimmer Biomet Holdings stock include Adam Rudolph Johnson, Blackstone Capital Partners V, Daniel E Williamson, Daniel P Florin, David A Jr Nolan, David C Dvorak, Stuart G Kleopfer and Tony W Collins.
Who sold Zimmer Biomet Holdings stock? Who is selling Zimmer Biomet Holdings stock?
Zimmer Biomet Holdings' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Bessemer Group Inc., Orbimed Advisors LLC, Tudor Investment Corp Et Al, Calamos Advisors LLC, Credit Agricole S A, AQR Capital Management LLC and NN Investment Partners Holdings N.V.. Company insiders that have sold Zimmer Biomet Holdings stock in the last year include Daniel E Williamson, Daniel P Florin, David A Jr Nolan, David C Dvorak, Stuart G Kleopfer and Tony W Collins.
Who bought Zimmer Biomet Holdings stock? Who is buying Zimmer Biomet Holdings stock?
Zimmer Biomet Holdings' stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Janus Capital Management LLC, FIL Ltd, Empire Life Investments Inc., State Street Corp, Asset Management One Co. Ltd., Tourbillon Capital Partners L.P. and Federated Investors Inc. PA.
How do I buy Zimmer Biomet Holdings stock?
Shares of Zimmer Biomet Holdings can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Zimmer Biomet Holdings stock cost?
One share of Zimmer Biomet Holdings stock can currently be purchased for approximately $116.92.